Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

June 03, 2019   |   June 2019 Bond Updates
OSLO, Norway, June 3, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a...

View more at: https://www.prnewswire.com:443/news-releases/targovax-announces-publication-of-in-vivo-abscopal-effect-of-oncos-102-and-keytruda-combination-300860388.html
Related News
Home| About us | Contact us http://www.bondupdatesdailynews.com/